Provision of a MassArray Mass-spectrometry based multiplex genotyping platform (Agena Biosciences).

Our genetics can predict our risk of disease and how we might respond drugs we are prescribed. Indeed, the application of genomics in to clinical practice within the NHS is happening at an ever quickening pace. The ability to develop and use data from panels of genetic variants in order to make treatment decisions is essential to this advancement.

In order to do so we require genetic testing equipment that is capable of typing for multiple genetic variant on a number of individuals in a cost-effective manner.

We propose to purchase a mass-spectrometry based genotyping platform (MassArray, Agena Biosciences). This equipment is capable of typing up to 40 genetic variants in 96 patient samples in a single run. The equipment would be able to undertake this analysis in a far more time, resource and cost efficient way than existing technologies we have at our disposal.

The proposed equipment will facilitate genetic analysis of samples from a range of human studies looking at disease risk and drug response across a diverse range of clinical areas. This includes studies in MRC priority areas such as infection and immunity and antimicrobial resistance.

The MassArray, has multiple capabilities enabling fast, automated genetic calling of samples. We will install it in Wolfson Centre for Personalised medicine at the University, an open access a large number from academia and industry users and collaborators. The equipment will serve a breadth of science across the MRC remit.